Evidence map›Paper›PMID 41005301›Full record

ArticleCell reports. Medicine2025

Chimeric hemagglutinin-based universal influenza mRNA vaccine induces protective immunity and bone marrow plasma cells in rhesus macaques.

Tiffany M Styles, Akil Akhtar, Chunyang Gu, Gabriele Neumann, Hiromi Muramatsu, Justine S McPartlan, Poulami Talukder, Derrik Gratz, Kasey Stokdyk, Hannah L Turner and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Tiffany M StylesEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA.
Akil AkhtarEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA.
Chunyang GuInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Gabriele NeumannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Justine S McPartlanTiba Biotech LLC, Cambridge, MA, 02142 USA.
Poulami TalukderTiba Biotech LLC, Cambridge, MA, 02142 USA.
Derrik GratzEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Kasey StokdykEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Hannah L TurnerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
James A FergusonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Alesandra J RodriguezDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Madhumathi LoganathanDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Benjamin FrancisDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anass AbbadDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghania ChikhAcuitas Therapeutics, Vancouver BC V6T 1Z3, Canada.
Ying K TamAcuitas Therapeutics, Vancouver BC V6T 1Z3, Canada.
Zhaohui S QinDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Julianna HanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jasdave S ChahalTiba Biotech LLC, Cambridge, MA, 02142 USA.
Christian W MandlTiba Biotech LLC, Cambridge, MA, 02142 USA.
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Pandemic Preparedness, Infection and Advanced Research Center, The University of Tokyo, Tokyo 162-8655, Japan.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
Rafi AhmedEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA.
Rama R AmaraEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA. Electronic address: ramara@emory.edu.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2M
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNAR01AI146101 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PARDI, NORBERT · 2019 to 2023
$3.1M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS R01 AI146101NIAID NIH HHS R01 AI153064
6 · The paper itself

Abstract

A universal influenza vaccine that elicits a strong and lasting stalk-specific antibody response is advantageous. We utilize nucleoside-modified mRNA in lipid nanoparticles (mRNA-LNP) and unmodified self-amplifying mRNA in modified dendritic nanoparticles (sam-MDNP), expressing chimeric hemagglutinin (cHA) antigens to induce stalk-specific humoral immunity in non-human primates with pre-existing influenza virus immunity. mRNA-LNP immunization induces strong stalk-specific binding antibodies capable of protecting mice from lethal heterologous influenza virus challenges and bone marrow plasma cells (BMPCs) that persist for up to 8 months. sam-MDNP vaccine induces lower humoral immunity, despite showing strong innate activation. Transcriptomic and cytokine analyses reveal a more persistent induction of interferon responses, interleukin (IL)-1β signaling, and IL-6 production in the mRNA-LNP group, correlating with the induction of serum antibody responses and BMPCs. These results identify a transcriptional signature associated with induction of BMPCs following mRNA vaccination and highlight the utility of cHA-based mRNA-LNP vaccines in inducing persistent stalk-directed protective antibody responses.

Indexed as

Bone Marrow CellsHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesPlasma CellsRNA, MessengerAnimalsAntibodies, ViralCytokinesFemaleImmunity, HumoralLiposomesMacaca mulattaMicemRNA VaccinesNanoparticlesOrthomyxoviridae InfectionsAntibodies, ViralCytokinesHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesLipid NanoparticlesLiposomesmRNA VaccinesRNA, Messengerbone marrow plasma cellschimeric hemagglutininmRNA-LNPrhesus macaquesself-amplifying mRNAtranscriptional signaturesuniversal influenza vaccine

Identifiers

PMID41005301
PMCPMC12629808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.